Agree the results look good. They have a huge body of data and evidence in these sort of indications through years of meandering through EPP cause and effects. I'm cautious on timelines because as we know with CUV time is not always the issue (sometimes understandable). The requirement of the further study for 10-17 YO and indication this is only a pre cursor to a larger phase 3 means some time to go I think. Progress is progress.
Ann: SCENESSE provides photoprotection in variegate porphyria, page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.72 |
Change
-0.100(0.67%) |
Mkt cap ! $737.1M | |||
| Open | High | Low | Value | Volume |
| $14.80 | $14.97 | $14.60 | $600.3K | 40.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 324 | $14.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.75 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |